BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 26139569)

  • 1. Acquired partial lipodystrophy is associated with increased risk for developing metabolic abnormalities.
    Akinci B; Koseoglu FD; Onay H; Yavuz S; Altay C; Simsir IY; Ozisik S; Demir L; Korkut M; Yilmaz N; Ozen S; Akinci G; Atik T; Calan M; Secil M; Comlekci A; Demir T
    Metabolism; 2015 Sep; 64(9):1086-95. PubMed ID: 26139569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum adiponectin and leptin levels in patients with lipodystrophies.
    Haque WA; Shimomura I; Matsuzawa Y; Garg A
    J Clin Endocrinol Metab; 2002 May; 87(5):2395. PubMed ID: 11994394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.
    Ozgen Saydam B; Sonmez M; Simsir IY; Erturk MS; Kulaksizoglu M; Arkan T; Hekimsoy Z; Cavdar U; Akinci G; Demir T; Altay CT; Mihci E; Secil M; Akinci B
    Endocr Res; 2019; 44(1-2):46-54. PubMed ID: 30182761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
    J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adipokines and highly active antiretroviral therapy related lipodystrophy: clinical study of 52 cases].
    Tao MM; Zhang L; Qiu ZF; Xie J; Han Y; Yu W; Li M; Li TS
    Zhonghua Yi Xue Za Zhi; 2009 Apr; 89(13):867-71. PubMed ID: 19671283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquired partial lipodystrophy with metabolic disease in children following hematopoietic stem cell transplantation: a report of two cases and a review of the literature.
    Hosokawa M; Shibata H; Hosokawa T; Irie J; Ito H; Hasegawa T
    J Pediatr Endocrinol Metab; 2019 May; 32(5):537-541. PubMed ID: 31075084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
    Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
    J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipodystrophy for the Diabetologist-What to Look For.
    Patni N; Garg A
    Curr Diab Rep; 2022 Sep; 22(9):461-470. PubMed ID: 35821558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
    Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy.
    Altay C; Seçil M; Adıyaman SC; Özgen Saydam B; Demir T; Akıncı G; Simsir IY; Eren E; Temeloğlu Keskin E; Demir L; Onay H; Topaloğlu H; Sarer Yürekli B; Özdemir Kutbay N; Gen R; Akıncı B
    Turk J Gastroenterol; 2020 Aug; 31(8):588-595. PubMed ID: 32915147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease.
    Hussain I; Patni N; Garg A
    Pathology; 2019 Feb; 51(2):202-212. PubMed ID: 30595509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement.
    Polyzos SA; Perakakis N; Mantzoros CS
    Metabolism; 2019 Jul; 96():66-82. PubMed ID: 31071311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic steatosis in Dunnigan-type familial partial lipodystrophy.
    Lüdtke A; Genschel J; Brabant G; Bauditz J; Taupitz M; Koch M; Wermke W; Worman HJ; Schmidt HH
    Am J Gastroenterol; 2005 Oct; 100(10):2218-24. PubMed ID: 16181372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher adiponectin levels in patients with Berardinelli-Seip congenital lipodystrophy due to seipin as compared with 1-acylglycerol-3-phosphate-o-acyltransferase-2 deficiency.
    Antuna-Puente B; Boutet E; Vigouroux C; Lascols O; Slama L; Caron-Debarle M; Khallouf E; Lévy-Marchal C; Capeau J; Bastard JP; Magré J
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1463-8. PubMed ID: 20097706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature.
    Misra A; Peethambaram A; Garg A
    Medicine (Baltimore); 2004 Jan; 83(1):18-34. PubMed ID: 14747765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study.
    Akinci B; Oral EA; Neidert A; Rus D; Cheng WY; Thompson-Leduc P; Cheung HC; Bradt P; Foss de Freitas MC; Montenegro RM; Fernandes VO; Cochran E; Brown RJ
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5120-5135. PubMed ID: 31314093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural History of Congenital Generalized Lipodystrophy: A Nationwide Study From Turkey.
    Akinci B; Onay H; Demir T; Ozen S; Kayserili H; Akinci G; Nur B; Tuysuz B; Nuri Ozbek M; Gungor A; Yildirim Simsir I; Altay C; Demir L; Simsek E; Atmaca M; Topaloglu H; Bilen H; Atmaca H; Atik T; Cavdar U; Altunoglu U; Aslanger A; Mihci E; Secil M; Saygili F; Comlekci A; Garg A
    J Clin Endocrinol Metab; 2016 Jul; 101(7):2759-67. PubMed ID: 27144933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.